By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with constipation. Lubiprostone was approved on January 31, 2006, for the treatment of chronic idiopathic constipation (CIC) in adults.
LubiprostoneSUCAMPO/TAKEDAChloride channel activator approved for chronic constipation
By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with constipation. Lubiprostone was approved on January 31, 2006, for the treatment of chronic idiopathic constipation (CIC) in adults.
Efficacy. The efficacy of lubiprostone in the treatment of CIC was evaluated in a dose-finding, double-blind, parallel-group, placebo-controlled phase 2 study of 127 patients with CIC. The patients were randomized to receive placebo or lubiprostone 24, 48, or 72 mcg/d. The primary efficacy variable in the study was the daily average number of spontaneous bowel movements (SBMs). The study demonstrated that all patients who received lubiprostone experienced a noticeable improvement in clinical response. There was no statistically significant improvement in clinical response beyond a total daily dose of 24 mcg. In 2 identical, double-blind, placebo-controlled studies, 479 patients with CIC were randomized to receive 4 weeks of either lubiprostone 24 mcg/bid or placebo. The primary end point of the studies was the SBM frequency following initiation of double-blind treatment. Patients receiving lubiprostone had a higher frequency of SBMs than patients receiving placebo during all 4 weeks of the study. At Week 4 of Study 1, patients in the lubiprostone group experienced a mean change in SBM rate from baseline of 3.9±4.6 versus 1.3±2.5 for patients in the placebo group. Similarly, at Week 4 of Study 2, patients in the lubiprostone group experienced a mean change in SBM rate from baseline of 4.1±4.8 versus 1.9±2.7 for patients in the placebo group. In both studies, lubiprostone treatment demonstrated increases in the percentage of patients who experienced SBMs within the first 24 hours after administration when compared with placebo (56.7% vs 36.9% in Study 1 and 62.9% vs 31.9% in Study 2).
Dosing. The recommended dose of lubiprostone is 24 mcg taken twice daily orally with food. Physicians and patients should periodically assess the need for continued therapy.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More